The COVID-19 pandemic created exceptional circumstances for virologists. To speed up the process from initial basic experiments to the final clinical application, appropriate reagents are required. Isolation of SARS-CoV-2-specific T cells via the MHC Streptamer® approach yields label-free, fully functional cells, making this method a valuable tool for high quality research.
Genoskin appointed CSO
AppointmentsDr Nicolas Gaudenzio has been started at the beginning of November as Chief Scientific Officer of Genoskin.
EC signs prepurchase agreement with Valneva
Latest NewsThe European Commission has inked the pre-purchase agreement over Valneva’s inactivated whole virus pandemic vaccine VLA2001 announed in mid-October.
Vifor buys out one-drug wonder Sanifit
Latest NewsSwiss Vifor Pharma is shelling out more than €375m for Mallorca-based Sanifit, a clinical-stage cardio-renal biopharmaceutical company with a single compound in development.
Novo Nordisk snatches Dicerna
Latest NewsNovo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.
Medical cannabis – Made in Germany
BackgroundOn 7th July 2021, the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte – BfArM) launched the first sale of cannabis exclusively for medical purposes from cultivation in Germany. Pharmacies are now able to purchase medical cannabis flowers of pharmaceutical drug quality for the supply of patients from the BfArM via the official portal of the German Cannabis Agency (www.cannabisagentur.de).
From interim to permanent
AppointmentsLotta Ferm, interim CFO of Immunicum AB, was now named as Chief Financial Officer.
Pfizer licences Paxlovid to poor countries
Latest NewsPfizer Inc announced it will allow generic makers in 95 low income nations to produce and distribute its COVID-19 pill Paxlovid at cost price.
Synthace bags US$35m for R&D cloud platform
Latest NewsLondon-based Synthace, which develops software to automate biology experimentation, has raised US$35m in a Series C from notable investors.
A SARS-CoV-2-specific T cell isolation method
Sponsored PublicationsThe COVID-19 pandemic created exceptional circumstances for virologists. To speed up the process from initial basic experiments to the final clinical application, appropriate reagents are required. Isolation of SARS-CoV-2-specific T cells via the MHC Streptamer® approach yields label-free, fully functional cells, making this method a valuable tool for high quality research.
BIAL with new R&D General Manager
AppointmentsBIAL, a public limited company under Portuguese law with head office in Coronado, Portugal, appointed Joerg Holenz as R&D General Manager and as a member of the Board of Directors.